BRAF and ganglioglioma: Particularly in gangliogliomas, which could compromise deep structures of the brain, preventing complete surgical resection and achieving adequate oncological control, BRAF V600E mutation could represent a druggable target for specific inhibitors such as vemurafenib or dabrafenib.